Using Filtered Forecasting Techniques to Determine Personalized Monitoring Schedules for Patients with Open-Angle Glaucoma

Gregory J. Schell, MSE,¹ Mariel S. Lavieri, PhD,¹ Jonathan E. Helm, PhD,² Xiang Liu, BSE,¹ David C. Musch, PhD, MPH,³,⁴ Mark P. Van Oyen, PhD,¹ Joshua D. Stein, MD, MS³

Purpose: To determine whether dynamic and personalized schedules of visual field (VF) testing and intraocular pressure (IOP) measurements result in an improvement in disease progression detection compared with fixed interval schedules for performing these tests when evaluating patients with open-angle glaucoma (OAG).

Design: Secondary analyses using longitudinal data from 2 randomized controlled trials.

Participants: A total of 571 participants from the Advanced Glaucoma Intervention Study (AGIS) and the Collaborative Initial Glaucoma Treatment Study (CIGTS).

Methods: Perimetric and tonometric data were obtained for AGIS and CIGTS trial participants and used to parameterize and validate a Kalman filter model. The Kalman filter updates knowledge about each participant’s disease dynamics as additional VF tests and IOP measurements are obtained. After incorporating the most recent VF and IOP measurements, the model forecasts each participant’s disease dynamics into the future and characterizes the forecasting error. To determine personalized schedules for future VF tests and IOP measurements, we developed an algorithm by combining the Kalman filter for state estimation with the predictive power of logistic regression to identify OAG progression. The algorithm was compared with 1-, 1.5-, and 2-year fixed interval schedules of obtaining VF and IOP measurements.

Main Outcome Measures: Length of diagnostic delay in detecting OAG progression, efficiency of detecting progression, and number of VF and IOP measurements needed to assess for progression.

Results: Participants were followed in the AGIS and CIGTS trials for a mean (standard deviation) of 6.5 (2.8) years. Our forecasting model achieved a 29% increased efficiency in identifying OAG progression ($P<0.0001$) and detected OAG progression 57% sooner (reduced diagnostic delay) ($P=0.02$) than following a fixed yearly monitoring schedule, without increasing the number of VF tests and IOP measurements required. The model performed well for patients with mild and advanced disease. The model performed significantly more testing of patients who exhibited OAG progression than nonprogressing patients (1.3 vs. 1.0 tests per year; $P<0.0001$).

Conclusions: Use of dynamic and personalized testing schedules can enhance the efficiency of OAG progression detection and reduce diagnostic delay compared with yearly fixed monitoring intervals. If further validation studies confirm these findings, such algorithms may be able to greatly enhance OAG management. Ophthalmology 2014;121:1539-1546 © 2014 by the American Academy of Ophthalmology.

Supplemental material is available at www.aaojournal.org.

When evaluating patients with glaucoma to assess for disease progression, clinicians must be able to assimilate past and present information from standard automated perimetry and other functional tests, intraocular pressure (IOP) measurements, and careful assessments of the optic nerve and retinal nerve fiber layer to decide whether patients are stable or exhibit disease progression and require changes in management. Complicating such an assessment is the presence of measurement error and variability in testing performance that is known to exist for many of these testing modalities. Studies have shown that the difficulties associated with evaluating patients with glaucoma to assess for disease progression have led to undertreatment¹,² and that decision aids, such as risk calculators,³ are useful supplements to clinician judgment. In this article, we present pilot data from a validation study of a decision aid tool that we hope someday will be able to assist clinicians with the management of patients with glaucoma. The tool assimilates data from past and present visual fields (VFs) and IOP measurements to determine whether a patient’s disease is stable and helps guide the timing of when the patient should next be examined to assess for disease progression.

At the core of this decision aid is a powerful statistical tool called “Kalman filtering,”¹ which models the motion of a dynamic system, forecasting the future trajectory and combining multiple measurements for optimal noise reduction.³ This technique is useful for accurately extracting state/position estimates from multiple noisy data sources. In the 1960s, the

ISSN 0161-6420/14/$ - see front matter
http://dx.doi.org/10.1016/j.ophtha.2014.02.021

© 2014 by the American Academy of Ophthalmology
Published by Elsevier Inc.
National Aeronautics and Space Administration used Kalman filtering to “optimally” guide Apollo missions to the moon. More recently, there has been interest in applying it to the management of chronic diseases, such as monitoring glucose levels in patients with diabetes mellitus and prostate-specific antigen levels in patients with prostate cancer. This approach builds a model that optimizes the timing of future tests by integrating a population-based understanding of the natural history of the disease of interest with the individual patient’s disease dynamics. When applied to glaucoma management, the model can be used to forecast future perimetric and tonometric measurements for individual patients. Unlike traditional approaches that identify glaucoma progression by comparing test results with a normative database, this approach generates personalized information on the disease state for each patient and forecasts how that state changes over time. By applying this to glaucoma management, it can be used to predict future values of the “positions” and respective velocities and accelerations of VF global indices, such as mean deviation (MD), pattern standard deviation (PSD), visual functional index, and IOP levels. One would expect these estimates to have increased accuracy over raw observations because the Kalman filter can optimally correct for measurement noise in the forecasts.

The purpose of this study is to determine whether the use of Kalman filtering to obtain personalized monitoring schedules of VF testing and IOP measurements for patients with open-angle glaucoma (OAG) results in an improvement in disease progression detection compared with 1-, 1.5-, and 2-year fixed interval schedules for performing these tests. By using longitudinal data from 2 randomized controlled trials of patients with OAG, we developed, parameterized, validated, and tested an algorithm that can determine whether each patient with OAG is stable or experiencing disease progression. The algorithm also dynamically determines the optimal time to perform the next test to monitor for OAG progression on the basis of information from the population that is integrated with past test results from the individual patient.

Methods

Data Sources
Data from 2 large, multicenter, randomized, controlled clinical trials, the Collaborative Initial Glaucoma Treatment Study (CIGTS) and Advanced Glaucoma Intervention Study (AGIS), were used for parameterization and validation of a Kalman filter and scheduling algorithm. These clinical trials were chosen because they included multiple measurements of IOP (by Goldmann applanation tonometry) and VF results (using a Humphrey Field Analyzer; Carl Zeiss Meditec, Dublin, CA) for patients with mild to advanced OAG over a period of up to 11 years and because they had highly structured follow-up examination regimens, with perimeter and tonometry performed every 6 months throughout the trials. In the CIGTS, 607 adults with newly diagnosed, early to moderate OAG were randomized to trabeculectomy or medical therapy and followed for up to 11 years to assess for disease progression. In the AGIS, 591 adults with advanced OAG were randomized to treatment with argon laser trabeculoplasty or trabeculectomy and followed for at least 5 years to check for OAG progression. The information contained in both the CIGTS and AGIS datasets was de-identified before we accessed it, and the University of Michigan Institutional Review Board determined that this study was exempt from requiring its approval.

Inclusion and Exclusion Criteria
To be included in our study, individuals from the 2 trials were required to have ≥4 examinations with VF and IOP readings. From both trials, we included only those participants who were treated with medical therapy or laser trabeculoplasty. Because incisional intraocular surgery can abruptly change glaucoma progression dynamics, we opted in this pilot study not to include data from those who were randomized to initial treatment with trabeculectomy, and those who underwent trabeculectomy during the course of either trial were censored at the time of their first trabeculectomy.

Data Elements
For each trial participant, we gathered demographic information on their age, sex, and race along with information on the IOP and VF performance at each visit. From every VF test performed on each patient throughout the trial, we extracted the MD and PSD values. By assessing global indices from serial VFs from the same patient over time, we calculated rates of change (i.e., velocity and acceleration) for MD and PSD. Velocity was computed per month, and acceleration was computed as the difference of the velocities from one period to the next period. We also calculated velocity and acceleration for IOP in a similar manner for each participant.

To validate and test our methodology, we divided the study’s CIGTS and AGIS trial data equally into a training set (for parameterizing models) and testing set (for validating and testing the models). We randomly assigned CIGTS/AGIS participants to these sets to ensure equal representation of both groups in the training and testing sets. We performed this randomization process 25 times and calibrated the Kalman filter for each randomization. The prediction error of the Kalman filter was consistently unbiased across the randomizations. We present the numeric results of one of these randomizations.

Probability of Progression
Progression Criterion. We characterized a participant in the dataset as exhibiting progression at a particular visit if he or she experienced a loss of MD of at least 3 decibels from their baseline MD and this loss was confirmed on a subsequent VF test. Because there is presently no gold standard for identifying progression on perimetric testing, we compared our progression definition with other progression measures, such as pointwise linear regression and change in Hodapp—Anderson—Parrish (HAP) classification (e.g., change from a HAP classification of moderate to a HAP classification of severe) and found strong similarities in progression identification (data not shown), suggesting robustness of the definition of progression we chose to use. Other progression definitions could easily be incorporated into the algorithm, contingent on the availability of all of the necessary data elements.

Logistic Regression
We developed a probability of progression function using generalized estimating equations with a logit link function and exchangeable correlation structure using the training data as inputs. This binary logistic regression approach accounted for noise in VF and IOP measurements and allowed us to assess the likelihood of a patient experiencing OAG progression at a particular visit given the patient’s specific characteristics (sex, age, race, baseline MD, present MD, MD velocity, MD acceleration, baseline PSD, present...
The Kalman Filter Approach (Time to Next Test Algorithm)

The time to next test (TNT) algorithm steps are illustrated in Figure 1. Key to the Kalman filter approach is its ability to incorporate the new test information with the data from all of the patient’s prior tests and the progression dynamics of the population. The algorithm requires a warm-up period of $\geq 3$ VF/IOP tests to calculate velocities and accelerations for MD, PSD, and IOP. Because the data from the AGIS and CIGTS trials were systematically collected every 6 months, it took a total of three 6-month periods (or 18 months) before the glaucoma decision aid could begin forecasting. Had the data from AGIS and CIGTS been collected at shorter time intervals between tests (e.g., every 3 months), the tool could begin forecasting sooner than a warm-up period of 18 months.

Once these are determined, the algorithm uses information about the underlying population and the particular patient’s test results to estimate the patient’s true MD, IOP, and PSD and respective velocities and accelerations of those parameters. When the algorithm receives new test measurements, the MD, PSD, IOP, and respective velocities and accelerations are updated using the Kalman filter, which is then used to forecast the patient’s mean values of MD, PSD, IOP, and respective velocities and accelerations for future time periods. The Kalman filter also provides an estimate of the variability of the forecasts with designated confidence intervals (CIs).

Figure 2 provides a graphic representation of how the progression threshold determines the time of the next test. The progression threshold (illustrated by the plane) separates the Kalman filter space into 2 regions: progression and nonprogression. This separation is performed by applying the logistic regression function to every point in the space. Those points with a calculated probability of progression less than the progression threshold are situated in the nonprogression region (to the left of the plane in Fig 2). Likewise, those points with a calculated probability of progression greater than or equal to the progression threshold are situated in the progression region (to the right of the plane in Fig 2).

In the execution of the TNT algorithm, we use the Kalman filter’s estimation of the mean and covariance of MD, PSD, IOP, and the respective velocities and accelerations to generate a confidence region (illustrated by the ellipsoid). For this confidence region, we compute the highest probability of progression using the logistic regression function. Once the highest probability of progression for the confidence region exceeds the progression threshold (i.e., at least one of the points of the confidence region falls into the progression region), the TNT algorithm suggests scheduling a VF and IOP test at that time (in this example, time t+4). The progression threshold and confidence region size can be tailored by the clinician to the needs of the individual patient to more or less aggressively monitor specific patients.

The TNT algorithm was parameterized using an expectation maximization algorithm. The expectation maximization algorithm is an iterative process that uses the training data to find the best estimates for the Kalman filter parameters. Next, using the testing dataset, we compared the performance of our scheduling algorithm with 1-, 1.5-, and 2-year fixed interval testing schedules for performing VFs and IOPs. To assess how well the algorithm performed relative to the fixed testing intervals, we compared (1) the average number of examinations (VFs and IOP measurements) performed per patient per year; (2) the efficiency in testing (percentage of instances where OAG progression was noted at the time a VF test and IOP measurement were scheduled); and (3) the diagnostic delay (average number of months that a patient’s glaucoma progression went undetected between examinations). We used asymptotic values for efficiency (e.g., 50% for 1-year fixed) and diagnostic delay (e.g., 3 months for 1-year fixed) as the performance measures for fixed interval schedules. This algorithm was applied to all trial participants in the testing dataset until a visit was scheduled on or after the date the patient first experienced glaucoma progression.

Analyses were run using MATLAB version 7.7.0 (The MathWorks Inc., Natick, MA) and R version 2.12.2 (http://www.r-project.org/). For all analyses, $P<0.05$ was considered statistically significant.

Results

A total of 571 participants (571 eyes) with OAG met the study inclusion criteria. Table 1 presents a summary of the participants. Of these, 266 (47%) came from CIGTS and 305 (53%) came from AGIS. The mean (standard deviation) age of the study participants at baseline was 63.2 (10.9) years. The participants included 272 male subjects (48%) and 299 female subjects (52%). There were 263 whites (46%) and 288 blacks (50%), and 20 were classified as some other race. Participants were followed in the trials for an average of 6.3 (2.8) years. The training dataset included 286 eyes of 286 patients, and the testing dataset included 285 eyes of 285 patients. There was no statistically significant difference in the demographic characteristics, number of visits, or clinical parameters (mean MD, PSD, IOP) between individuals in the training and testing datasets ($P>0.05$ for all comparisons), except there were slightly more blacks in the training set than the testing set ($154$ vs. $134; P = 0.05$).
Identification of Open-Angle Glaucoma Progression

Ophthalmology Volume 121, Number 8, August 2014

Table 1. Description of Study Sample of Patients from the Collaborative Initial Glaucoma Treatment Study/Advanced Glaucoma Intervention Study

<table>
<thead>
<tr>
<th>Training</th>
<th>Testing</th>
<th>P Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>%</td>
<td>n</td>
</tr>
<tr>
<td>No. of eyes</td>
<td>286</td>
<td>283</td>
</tr>
<tr>
<td>No. of participants</td>
<td>286</td>
<td>285</td>
</tr>
<tr>
<td>No. from CIGTS</td>
<td>131</td>
<td>46</td>
</tr>
<tr>
<td>No. from AGIS</td>
<td>155</td>
<td>54</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>135</td>
<td>47</td>
</tr>
<tr>
<td>Female</td>
<td>151</td>
<td>53</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>123</td>
<td>43</td>
</tr>
<tr>
<td>Black</td>
<td>154</td>
<td>54</td>
</tr>
<tr>
<td>Other</td>
<td>9</td>
<td>3</td>
</tr>
<tr>
<td>Total no. of visits</td>
<td>3158</td>
<td>3227</td>
</tr>
<tr>
<td>No. of instances of progression</td>
<td>163</td>
<td>166</td>
</tr>
</tbody>
</table>

AGIS = Advanced Glaucoma Intervention Study; CIGTS = Collaborative Initial Glaucoma Treatment Study; IOP = intraocular pressure; MD = mean deviation; PSD = pattern standard deviation; SD = standard deviation.

*P values are calculated for the null hypothesis of equal proportion in testing and training set for categorical variables and the null hypothesis of equal means for continuous variables.

Logistic Regression

Table 2 presents the coefficients, standard errors, and P values of the covariates incorporated into the logistic regression, which we then used to assess the probability of OAG progression for each patient. As expected, patients with more advanced glaucoma as captured on perimetry (a more negative MD or a more positive PSD) had a higher probability of progression compared with those with less advanced disease. In the regression model, each of the covariates in Table 2 was found to be significantly associated with OAG progression (P<0.04 for each covariate).

Validation of Kalman Filter

To validate the fit and predictive ability of the Kalman filter for assessing OAG progression, we calculated the 95% CIs for the mean prediction errors of MD, PSD, and IOP and their respective velocities and accelerations across all study participants in the testing dataset. Errors were calculated at various prediction lengths (6 months, 2 years, and 5 years into the future). Table 3 (available at www.aaojournal.org) shows that the mean differences between the Kalman filter predictions and the observed values from the trials were close to zero across various prediction lengths (z = 0.05), supporting the accuracy of the Kalman filter predictions.

Next, we compared the observed values of MD from each clinical trial participant in the testing dataset with the filtered and predicted values of MD generated by the Kalman filter. The Kalman filter forecasts one period ahead and updates the forecasts with the clinical observation for that period to obtain the filtered estimate of MD at each sequential trial visit. Predicted MD values are those obtained from the Kalman filter without incorporating future clinical observations. To illustrate the Kalman filter’s forecasting ability (Fig 3), we present 4 study participants, 2 of whom exhibited OAG progression and 2 of whom experienced no progression during their enrollment in one of the clinical trials. We also estimated 90% CIs for the predicted values toward the end of each participant’s enrollment in the clinical trial. We chose the narrower 90% CIs for the predicted values to demonstrate how strong the predictive power of the Kalman filter actually is. Because all observations fell well within the 90% CIs, the observations would also fall within the wider 95% CIs. We found that at all future time points, the Kalman filter forecasts for MD were close to the observed MD values obtained when the participant took the test during the clinical trial; our CIs for predicted MD fully encompassed the observed MD values, even 3.5 years into the future. Similar analyses were performed on all patients in the testing set for PSD and IOP. Figure 4 (available at www.aaojournal.org) shows an example of how the algorithm forecasts future PSD and IOP measurements.

The Kalman filter assumes the process and measurement noise are normally distributed. We have examined the errors and found that normality holds within 2 standard deviations of the mean for all of the Kalman filter variables (MD, PSD, IOP, and their respective velocities and accelerations) (data not shown).

Kalman Filter Versus Fixed Testing Intervals to Identify Open-Angle Glaucoma Progression

After calibrating the TNT algorithm, we evaluated the algorithm with fixed testing intervals of 1, 1.5, and 2 years. Our evaluation involved assessing the (1) number of tests, (2) efficiency, and (3) diagnostic delay. Figure 5 compares the average efficiency and diagnostic delay of the TNT algorithm and the 1-, 1.5-, and 2-year fixed testing intervals. For the same average number of tests as the 1-, 1.5-, and 2-year fixed testing intervals, the TNT algorithm achieved higher efficiency (P<0.0001 for all comparisons) and.

Table 2. Factors in Multivariable Logistic Regression Associated with Open-Angle Glaucoma Progression

<table>
<thead>
<tr>
<th>Covariate</th>
<th>Coefficient</th>
<th>Standard Error</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intercept</td>
<td>-6.004</td>
<td>0.723</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>MD (dB)</td>
<td>-0.057</td>
<td>0.017</td>
<td>0.001</td>
</tr>
<tr>
<td>MD velocity (dB/mo)</td>
<td>-0.054</td>
<td>0.066</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>MD acceleration (dB/6 mo²)</td>
<td>-1.183</td>
<td>0.326</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Baseline PSD (dB)</td>
<td>-0.162</td>
<td>0.078</td>
<td>0.039</td>
</tr>
<tr>
<td>PSD (dB)</td>
<td>0.154</td>
<td>0.075</td>
<td>0.039</td>
</tr>
<tr>
<td>Age (yrs)</td>
<td>0.026</td>
<td>0.103</td>
<td>0.013</td>
</tr>
</tbody>
</table>

dB = decibels; MD = mean deviation; PSD = pattern standard deviation.
reduced diagnostic delay ($P = 0.02$, $P < 0.0001$, and $P < 0.0001$, respectively) for detecting OAG progression. For example, when comparing the 1-year fixed testing interval with the TNT algorithm, for the same average number of tests (4.7 tests), the TNT algorithm increased efficiency by 29% and reduced diagnostic delay at OAG progression detection by 1.7 months.

Table 4 shows how the algorithm performed in the subset of participants enrolled in both trials who experienced OAG progression compared with those who never experienced glaucoma progression. Overall, 116 trial participants in the testing dataset were noted to have OAG progression and 169 participants did not exhibit progression. Among those in the testing dataset who progressed, the mean (standard deviation) time from study enrollment to the first record of OAG progression was 45.7 (23.4) months. Because efficiency and diagnostic delay assess the algorithm’s ability to schedule follow-up tests at times when there was evidence of actual OAG progression, these performance measures were not applicable for the subset of participants who did not exhibit disease progression. The algorithm scheduled more tests per year for patients who were exhibiting OAG progression (1.3 vs. 0.9 average tests per year; $P < 0.0001$). The TNT algorithm achieved marginally improved efficiency (83% vs. 71%; $P = 0.06$) for AGIS patients compared with CIGTS patients, and the efficiency of OAG progression detection for both groups was better than the efficiency achieved using 1-year fixed testing.

Table 4 also shows how the TNT algorithm performed on CIGTS patients and AGIS patients in the testing dataset separately. As one might expect, the TNT algorithm scheduled more tests for AGIS patients than for CIGTS patients (1.3 vs. 0.9 average tests per year; $P < 0.0001$). The TNT algorithm achieved marginally improved efficiency (83% vs. 71%; $P = 0.06$) for AGIS patients compared with CIGTS patients, and the efficiency of OAG progression detection for both groups was better than the efficiency achieved using 1-year fixed testing.
intervals (50%). Diagnostic delay at detecting OAG progression (1.0 vs. 1.9 months; \(P = 0.09\)) was slightly shorter for AGIS patients, although this did not reach statistical significance.

Additional analyses were performed to see how well the TNT algorithm performed on black versus white patients from the trials. We found that the TNT algorithm performed more tests on average for black patients than white patients (5.31 vs. 4.24; \(P = 0.03\)). The TNT algorithm performed equally well in terms of efficiency and diagnostic delay (\(P = 0.10\) and 0.20, respectively) for black and white patients.

**Discussion**

By using a forecasting technique called Kalman filtering, we parameterized an algorithm that dynamically updates the timing of future measurements for each individual on the basis of prior measurements. The Kalman filter starts with information about the population, and as patient observations are obtained, the Kalman filter incorporates these data to learn about each individual’s specific progression.

**Table 4. Comparison of Algorithm Performance for Progressing versus Nonprogressing Patients and Advanced Glaucoma Intervention Study versus Collaborative Initial Glaucoma Treatment Study Patients**

<table>
<thead>
<tr>
<th>Performance Measures</th>
<th>1-Year Fixed Interval Testing</th>
<th>TNT of All Patients</th>
<th>TNT of Progressing Patients</th>
<th>TNT of Nonprogressing Patients</th>
<th>TNT of AGIS Patients</th>
<th>TNT of CIGTS Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average no. of tests per year</td>
<td>1.00</td>
<td>1.12</td>
<td>1.28</td>
<td>1.02</td>
<td>1.30</td>
<td>0.92</td>
</tr>
<tr>
<td>Average efficiency (%)</td>
<td>50</td>
<td>79</td>
<td>79</td>
<td>N/A</td>
<td>83</td>
<td>71</td>
</tr>
<tr>
<td>Average diagnostic delay (mos)</td>
<td>3.00</td>
<td>1.29</td>
<td>1.29</td>
<td>N/A</td>
<td>1.02</td>
<td>1.92</td>
</tr>
</tbody>
</table>

AGIS = Advanced Glaucoma Intervention Study; CIGTS = Collaborative Initial Glaucoma Treatment Study; TNT = time to next test algorithm; N/A = not applicable.

Progressing patients are those who met our definition of progression (loss of 3 decibels mean deviation [MD] from baseline) at least once during their enrollment in the clinical trial. Nonprogressing patients are those who never met the definition of progression during their time in AGIS/CIGTS. Efficiency is the percentage of instances where open-angle glaucoma progression was noted at the time a test was scheduled. Diagnostic delay is the number of months that a patient’s glaucoma progression went undetected between examinations.
dynamics. Our algorithm was validated using longitudinal data from 2 large, multicenter clinical trials of patients with mild to advanced OAG. By comparing the output generated from the algorithm with fixed testing intervals of 1, 1.5, and 2 years, we show that the algorithm is capable of detecting OAG progression more efficiently and with reduced diagnostic delay compared with fixed interval schedules, without the need for additional tests. The model seems to work well for those with mild to moderate OAG (participants in CIGTS) and those with more advanced disease (participants in AGIS), performs well for the subset of trial participants who did and did not exhibit OAG progression, and forecasts well for white and black trial participants.

Although we are unaware of other personalized algorithms that use a Kalman filter to determine the frequency of testing of patients with OAG or other ophthalmological diseases, this approach is being applied in other medical specialties to aid clinicians in clinical decision making for patients with chronic diseases. Examples include estimation of pulmonary blood flow\(^{12,13}\) and prediction of arterial blood pressure.\(^1\) This approach lends itself well to progressive conditions that involve repeated testing using quantitative data.

There are several advantages to using this approach to aid in evaluating and monitoring of patients with OAG, rather than simply testing all patients at fixed intervals or relying on one’s gestalt of how often to monitor a given patient. By incorporating data from a population of patients with OAG, the Kalman filter is able to identify and filter out systematic noise (e.g., measurement error, variability in test performance) that is known to exist in IOP readings and VF test results. Second, the Kalman filter makes use of data from sequential visits to account for the disease dynamics of each individual patient and continually updates the model with new test results after each visit to determine the timing of future testing. Third, the algorithm is scalable and can include additional data from structural tests, such as optical coherence tomography or confocal scanning laser ophthalmoscopy, as well as other quantifiable data elements. Fourth, because there is presently no consensus on the optimal approach to define OAG progression, the model is flexible enough to be able to make predictions of progression using different definitions. Finally, the algorithm can be tailored by the eye care provider to be more or less aggressive in testing for disease progression. For example, the algorithm can be modified so that a clinician can choose to increase the threshold for detecting OAG progression for an 85-year-old patient with early OAG who has multiple medical comorbidities, if the clinician thinks this patient is unlikely to go blind from the disease, so as to not overburden such a patient with frequent tests. Alternatively, for a 40-year-old monocular patient with severe OAG, the clinician might opt to lower the threshold so that the algorithm can identify the first hint of possible disease progression. From a societal perspective, the use of Kalman filter forecasting can improve the quality of care offered to patients by aiding in more timely identification of those who are exhibiting OAG progression and require additional treatment while simultaneously limiting patient burden and added costs of performing unnecessary testing.

Study Limitations

First, the types of parameters that we were able to incorporate into the Kalman filter we developed were limited to those that were measured in the CIGTS and AGIS studies. Information that we would have liked to include in the algorithm but was not available from those trials includes pachymetry readings, optical coherence tomography measurements, and other quantifiable measures of the optic nerve or retinal nerve fiber layer. In the future, we hope to obtain access to datasets that longitudinally capture information on these parameters so we can refine our algorithm, which should enhance its ability to identify people who are at increased risk of OAG progression. Second, we have yet to test this algorithm on other groups of patients, such as those with ocular hypertension, early preperimetric glaucoma, or other forms of glaucoma, and those who underwent incisional glaucoma surgery. Further validation is necessary to determine how well the algorithm predicts disease progression and need for monitoring in these groups. Third, the timing of the follow-up examinations in the AGIS and CIGTS restricted our algorithm’s scheduling decisions to no more frequently than every 6 months. If follow-up examination data for smaller time windows (e.g., every 1 month) were available, our algorithm could make scheduling decisions as often as every month. As we shorten the time interval allowed in scheduling (e.g., 6 months to 1 month), we expect the algorithm to achieve higher efficiency and lower diagnostic delay. In particular, this would allow for large gains in the improvement of our TNT algorithm for diagnostic delay. The exact gains cannot be known until we have tested our TNT algorithm on data collected at a higher frequency of every 1 or 3 months. Last, patient adherence to prescribed medications is likely higher for participants in the AGIS and CIGTS compared with those routinely cared for in clinical practice. When applied to patients seen in clinical practice, the increased IOP variability due to lower medication adherence would likely decrease the predictive capability of the Kalman filter. When we further validate the model using another sample of patients who were not enrolled in a clinical trial, we will be able to explore this further.

There are also algorithm limitations to mention. First, the Kalman filter assumes glaucoma evolves linearly over time. To address potential nonlinear evolution, we modeled the velocity and acceleration of MD, PSD, and IOP in the Kalman filter. Second, our approach requires a 3-period warm-up so that we can calculate velocity and acceleration. This warm-up delays when the algorithm can begin predicting the optimal timing of the next test. However, outside of a clinical trial setting (in clinical practice), these 3 measurements could be acquired more quickly than every 6 months so the model does not require 18 months before it begins generating forecasts.

In conclusion, we have developed, parameterized, and validated an algorithm that forecasts the probability of OAG progression using a filtered forecasting technique and helps identify the optimal timing to perform additional testing for patients with mild to advanced OAG. With each additional
set of measurements obtained, the algorithm updates its predictions so that it generates a personalized assessment of each patient’s risk of progression and the timing of additional testing. The algorithm is scalable and gives clinicians the ability to input how aggressively they want to manage a given patient. When the algorithm was tested in a group of patients from the CIGTS and AGIS trials, it performed considerably better than 1-, 1.5-, and 2-year fixed-interval testing schedules. With further refinement of this algorithm and after additional validation studies are performed using patients with other forms of glaucoma, we hope that such an algorithm will soon be accessible in a user-friendly format to enhance the ability of clinicians to effectively care for patients with OAG.

Acknowledgments. The authors thank Leslie Niziol, MS, for formatting the data from CIGTS; Paul Van Veldhuisen, PhD, for providing the data from AGIS; and the following undergraduate students for assistance in coding and analysis of clinical trial data: Jade Watts, Amanda Bayagich, Xiang Li, and Sam Devaprasad.

References


Footnotes and Financial Disclosures


1 Department of Industrial and Operations Engineering, University of Michigan School of Engineering, Ann Arbor, Michigan.
2 Department of Operations and Decision Technologies, Indiana University Kelley School of Business, Bloomington, Indiana.
3 Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan.
4 Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan.

Presented in part at: the American Glaucoma Society Annual Meeting, March 2, 2013, San Francisco, California; and the Association for Research in Vision and Ophthalmology, May 7, 2013, Seattle, Washington. Financial Disclosure(s): The author(s) have made the following disclosure(s): The authors of this work have a Provisionary Patent 010109-11001P filed with the U.S. Office of Patents, which covers intellectual property described in this manuscript.

Partial funding for this work has been received from National Institutes of Health Clinical and Translational Science Award Grant UL 1RR024986 and National Science Foundation Grant CMMI-1161439. The funding organizations had no role in the design or conduct of this research.

Abbreviations and Acronyms:
AGIS = Advanced Glaucoma Intervention Study; CI = confidence interval; CIGTS = Collaborative Initial Glaucoma Treatment Study; HAP = Hodapp–Anderson–Parrish; IOP = intraocular pressure; MD = mean deviation; OAG = open-angle glaucoma; PSD = pattern standard deviation; TNT = Time to Next Test; VF = visual field.